Drug Approval | February 21, 2025
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
No safety signals related to the vaccine candidate were identified
Offers affordable, high-quality solutions for diabetes care
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Plans underway to expand screening capacity by 50% for greater accessibility
Subscribe To Our Newsletter & Stay Updated
